GLOBAL RAT MODEL MARKET FORECAST 2017-2025
KEY FINDINGS
The global rat model market was worth $434283 thousand in the year 2016 and is expected to grow at a CAGR of 9.55% for the forecast period of 2017-2025. It is anticipated that the market worth would be around $985778 thousand by the year 2025. The main reason for the potential growth of the market is the fact that the rat models are more suitable for medical as well as pharmaceutical research as compared to other animal models used.
MARKET INSIGHTS
The global rat model market can be segmented on the basis of various categories like application, rat model types, components, and rat care products. Rapid and increasing availability in rat transgenic methodologies, improving genome editing techniques and the growing research and developments in pharmaceutical and biotechnological companies are the major drivers for the growth of the rat model market. The oncology application market is fast growing at a CAGR of 11.17%. However, the toxicology market is currently dominating the application segment of the market. The Immunology & Inflammation markets is expected to grow at a CAGR of9.95% during the forecast period. With respect to the types of rat models, the current market scenario shows an anticipated CAGR of 8.63%, 9.84%, 9.66%, and 10.11% respectively for the inbred rats, immune-deficient rat, surgically modified rats, and hybrid type rat model. The rat care product had contributed to 1.95% of the market share in the year 2016 and is expected to grow at a CAGR of 9.42% by the year 2025.
REGIONAL INSIGHTS
The North-American rat model market is expected to hold the highest share by the year 2025 with the US market contributing to the majority of the share owing to the increased demand for rat models in the pre-clinical animal trials by companies such as Novartis, Merck &Co, Roche etc. in this region. The Asia-Pacific market is fast flourishing, especially in regions like India, China, and Australia because of the novel R&D incentive schemes for the pharmaceutical companies and the Contract Research Organizations. The market is predicted to grow at a CAGR of 9.11 % during the forecast period. The United Kingdom is currently the leader in the European rat model market mainly because of the lucrative R&D revenue schemes and the growing interest of the commercial investors in the region.
COMPETITIVE INSIGHTS
The major players in the global rat model market are Covance Inc. (LabCorp holding company), Janvier labs, Harlan Laboratories, Inc. (Envigo, Inc. Holding company),Sage Labs Inc. (horizon discovery group plc holding company), Cyagen Biosciences Inc, Transposagen Biopharmaceuticals Inc. Transviragen Inc., Taconic Biosciences, Hera Biolabs Inc., Genoway S.A Vivo Biotech ltd., Charles River Laboratories, Sage Labs, Covance Inc., Clea Japan, and Oncodesign s.a. . Labcorp Ltd has the largest laboratory network around the world with most of its research focusing on genomics.
The global rat model market was worth $434283 thousand in the year 2016 and is expected to grow at a CAGR of 9.55% for the forecast period of 2017-2025. It is anticipated that the market worth would be around $985778 thousand by the year 2025. The main reason for the potential growth of the market is the fact that the rat models are more suitable for medical as well as pharmaceutical research as compared to other animal models used.
MARKET INSIGHTS
The global rat model market can be segmented on the basis of various categories like application, rat model types, components, and rat care products. Rapid and increasing availability in rat transgenic methodologies, improving genome editing techniques and the growing research and developments in pharmaceutical and biotechnological companies are the major drivers for the growth of the rat model market. The oncology application market is fast growing at a CAGR of 11.17%. However, the toxicology market is currently dominating the application segment of the market. The Immunology & Inflammation markets is expected to grow at a CAGR of9.95% during the forecast period. With respect to the types of rat models, the current market scenario shows an anticipated CAGR of 8.63%, 9.84%, 9.66%, and 10.11% respectively for the inbred rats, immune-deficient rat, surgically modified rats, and hybrid type rat model. The rat care product had contributed to 1.95% of the market share in the year 2016 and is expected to grow at a CAGR of 9.42% by the year 2025.
REGIONAL INSIGHTS
The North-American rat model market is expected to hold the highest share by the year 2025 with the US market contributing to the majority of the share owing to the increased demand for rat models in the pre-clinical animal trials by companies such as Novartis, Merck &Co, Roche etc. in this region. The Asia-Pacific market is fast flourishing, especially in regions like India, China, and Australia because of the novel R&D incentive schemes for the pharmaceutical companies and the Contract Research Organizations. The market is predicted to grow at a CAGR of 9.11 % during the forecast period. The United Kingdom is currently the leader in the European rat model market mainly because of the lucrative R&D revenue schemes and the growing interest of the commercial investors in the region.
COMPETITIVE INSIGHTS
The major players in the global rat model market are Covance Inc. (LabCorp holding company), Janvier labs, Harlan Laboratories, Inc. (Envigo, Inc. Holding company),Sage Labs Inc. (horizon discovery group plc holding company), Cyagen Biosciences Inc, Transposagen Biopharmaceuticals Inc. Transviragen Inc., Taconic Biosciences, Hera Biolabs Inc., Genoway S.A Vivo Biotech ltd., Charles River Laboratories, Sage Labs, Covance Inc., Clea Japan, and Oncodesign s.a. . Labcorp Ltd has the largest laboratory network around the world with most of its research focusing on genomics.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. IMPROVEMENT IN GENOME EDITING
4.1.2. FAST AND INCREASING AVAILABILITY IN RAT TRANSGENIC
4.1.3. INCREASING PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES R&D
4.2. MARKET RESTRAINTS
4.2.1. PRACTICE OF ANIMALS IN RESEARCH IS CONSIDERED UNETHICAL
4.2.2. FLUCTUATING RULES AND REGULATION ON ANIMAL TESTING
4.2.3. USE OF ZEBRA FISH IN RESEARCH IS THE GROWING MODEL
4.2.4. IN VITRO AND ALTERNATIVE TESTING TECHNIQUES MODELS FOR RESEARCH
4.3. MARKET OPPORTUNITIES
4.3.1. RISING DEMAND OF RAT MODEL FOR RESEARCH ACTIVITIES FROM EMERGENT ECONOMIES
4.3.2. PERSONALIZED MEDICINE ESTABLISHED TO SURGE DEMAND
4.3.3. ESCALATION IN MONOCLONAL ANTIBODY CREATION
4.4. MARKET CHALLENGES
4.4.1. RAT MODEL IS HIGHLY EXPENSIVE
5. MARKET SEGMENTATION
5.1. BY RAT MODEL TYPES
5.1.1. INBRED RATS
5.1.2. KNOCKOUT/GENETICALLY ENGINEERED RATS
5.1.3. HYBRID/CONGENIC RATS
5.1.4. OUTBRED RATS
5.1.5. IMMUNE-DEFICIENT RATS
5.1.6. CONDITIONED/SURGICALLY MODIFIED RATS
5.2. BY COMPONENTS
5.2.1. TECHNOLOGY
5.2.1.1. NUCLEAR TRANSFERASE TECHNOLOGY
5.2.1.2. MICROINJECTION
5.2.1.3. EMBRYONIC STEM CELL INJECTION
5.2.1.4. OTHER TECHNOLOGY
5.2.2. SERVICES
5.2.3. RAT CARE PRODUCTS
5.2.3.1. FEED
5.2.3.2. BEDDING
5.2.3.3. CAGES
5.2.3.4. OTHER CARE PRODUCTS
5.3. BY APPLICATION
5.3.1. DIABETES
5.3.2. TOXICOLOGY
5.3.3. ONCOLOGY
5.3.4. IMMUNOLOGY & INFLAMMATION
5.3.5. OTHER
6. KEY ANALYTICS
6.1. PORTERS 5 FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCT
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. VALUE CHAIN ANALYSIS
6.4. OPPORTUNITY MATRIX
6.5. REGULATORY FRAMEWORK
6.6. ESTIMATION ANALYSIS
6.6.1. GLOBAL BIOTECH INVESTMENT
6.6.2. BIOTECHNOLOGY FIRMS ACROSS COUNTRIES
6.6.3. GLOBAL PHARMACEUTICAL RESEARCH & DEVELOPMENT EXPENDITURE
6.6.4. GLOBAL BIOTECH R&D EXPENDITURE
6.7. KEY BUYING CRITERIA
6.7.1. HIGH ACCURACY
6.7.2. HIGH EFFICACY
6.7.3. QUALITY OF OPERATING PROCEDURE
6.7.4. PRICE
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. U.S.
7.1.2. CANADA
7.2. EUROPE
7.2.1. UNITED KINGDOM
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. SPAIN
7.2.5. ITALY
7.2.6. REST OF EUROPE (ROE)
7.3. ASIA PACIFIC
7.3.1. CHINA
7.3.2. INDIA
7.3.3. JAPAN
7.3.4. SOUTH KOREA
7.3.5. AUSTRALIA
7.3.6. REST OF ASIA-PACIFIC
7.4. REST OF THE WORLD
7.4.1. LATIN AMERICA
7.4.2. MIDDLE EAST AND NORTH AFRICA
7.4.3. AFRICA
8. COMPETITIVE ANALYSIS
8.1. KEY STRATEGIES AND ANALYSIS
8.1.1. MERGER & ACQUISITION (M&A)
8.1.2. COLLABORATION & PARTNERSHIPS
8.1.3. INVESTMENT / PRODUCT LAUNCH
8.2. MARKET SHARE
8.3. TOP COMPANY ANALYSIS
8.4. LIST OF M&A
8.5. COLLABORATION & PARTNERSHIP
8.6. LIST OF PRODUCT LAUNCHES
9. COMPANY PROFILE
9.1. BIOMEDICAL RESEARCH MODEL INC.
9.1.1. COMPANY OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.2. CHARLES RIVER LABORATORIES INC.
9.2.1. COMPANY OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. KEY INNOVATION SECTOR
9.2.4. STRATEGIC INITIATIVES
9.2.5. SCOT ANALYSIS
9.3. COVANCE INC. (LABCORP HOLDING COMPANY)
9.3.1. COMPANY OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. KEY INNOVATION SECTOR
9.3.4. STRATEGIC INITIATIVES
9.3.5. SCOT ANALYSIS
9.4. GENOWAY S. A.
9.4.1. COMPANY OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. KEY INNOVATION SECTOR
9.4.4. STRATEGIC INITIATIVES
9.4.5. SCOT ANALYSIS
9.5. HARLAN LABORATORIES, INC. (ENVIGO, INC. HOLDING COMPANY)
9.5.1. COMPANY OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC INITIATIVES
9.5.4. SCOT ANALYSIS
9.6. JANVIER LABS
9.6.1. COMPANY OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. SAGE LABS INC (HORIZON DISCOVERY GROUP PLC HOLDING COMPANY)
9.7.1. COMPANY OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVES
9.7.4. SCOT ANALYSIS
9.8. TACONIC BIOSCIENCES
9.8.1. COMPANY OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. KEY INNOVATION SECTOR
9.8.4. STRATEGIC INITIATIVES
9.8.5. SCOT ANALYSIS
9.9. TRANSPOSAGEN BIOPHARMACEUTICALS INC
9.9.1. COMPANY OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. KEY INNOVATION SECTOR
9.9.4. STRATEGIC INITIATIVES
9.9.5. SCOT ANALYSIS
9.10. TRANSVIRAGEN INC.
9.10.1. COMPANY OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. HERA BIOLABS INC.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. KEY INNOVATION SECTOR
9.11.4. STRATEGIC INITIATIVE
9.11.5. SCOT ANALYSIS
9.12. ONCODESIGN S.A.
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. KEY INNOVATION SECTOR
9.12.4. STRATEGIC INITIATIVE
9.12.5. SCOT ANALYSIS
9.13. CYAGEN BIOSCIENCES INC.
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. KEY INNOVATION SECTOR
9.13.4. STRATEGIC INITIATIVE
9.13.5. SCOT ANALYSIS
9.14. IVO BIOTECH LTD.
9.14.1. COMPANY OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC INITIATIVES
9.14.4. SCOT ANALYSIS
9.15. CLEA JAPAN
9.15.1. COMPANY OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC INITIATIVES
9.15.4. KEY INNOVATION SECTOR
9.15.5. SCOT ANALYSIS
9.16. TRANSVIRAGEN, INC.
9.16.1. COMPANY OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC INITIATIVES
9.16.4. KEY INNOVATION SECTOR
9.16.5. SCOT ANALYSIS
9.17. BIOMERE
9.17.1. COMPANY OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC INITIATIVES
9.17.4. KEY INNOVATION SECTOR
9.17.5. SCOT ANALYSIS
9.18. LABORATORY CORPORATION OF AMERICA HOLDINGS
9.18.1. COMPANY OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. STRATEGIC INITIATIVES
9.18.4. KEY INNOVATION SECTOR
9.18.5. SCOT ANALYSIS
TABLE LIST
TABLE 1 GLOBAL RAT MODEL MARKET BY GEOGRAPHIC REGION 2017-2025 ($ THOUSAND)
TABLE 2 BENEFITS OF RATS
TABLE 3 GLOBAL RATS MODEL MARKET BY RAT TYPES 2017-2025 ($ THOUSAND)
TABLE 4 EXAMPLES OF INBRED RATS AND THERE RESEARCH APPLICATIONS
TABLE 5 GLOBAL INBRED RATS TYPE BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 6 GLOBAL GENETICALLY ENGINEERED RATS MARKET BY GEOGRAPHY 2017-2025($ THOUSAND)
TABLE 7 GLOBAL HYBRID RATS MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 8 EXAMPLES OF OUTBRED RATS AND THERE RESEARCH APPLICATIONS
TABLE 9 GLOBAL OUTBRED RATS MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 10 GLOBAL IMMUNE DEFICIT RATS MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 11 GLOBAL SURGICALLY MODIFIED RATS MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 12 GLOBAL RATS MODEL MARKET BY COMPONENTS 2017-2025 ($ THOUSAND)
TABLE 13 GLOBAL RATS MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 14 GLOBAL NUCLEAR TRANSFER TECHNOLOGY BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 15 GLOBAL MICRO INJECTION TECHNOLOGY BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 16 GLOBAL EMBRYONIC STEM CELL INJECTION TECHNOLOGY BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 17 GLOBAL OTHER TECHNOLOGY RAT MODEL MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 18 GLOBAL RAT MODEL SERVICES MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 19 GLOBAL RAT MODEL MARKET BY RAT CARE PRODUCTS 2017-2025 ($ THOUSAND)
TABLE 20 GLOBAL RAT FEED MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 21 POPULAR FOOD FOR RATS
TABLE 22 GLOBAL RAT BEDDING MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 23 GLOBAL RAT CAGES MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 24 GLOBAL RAT CARE OTHERS MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 25 GLOBAL RAT MODEL MARKET BY APPLICATION 2017-2025($ THOUSAND)
TABLE 26 GLOBAL DIABETES RAT MODEL MARKET BY REGION 2017-2025($ THOUSAND)
TABLE 27 GLOBAL ONCOLOGY RAT MODEL MARKET BY REGION 2017-2025($ THOUSAND)
TABLE 28 GLOBAL IMMUNOLOGY & INFLAMMATION RAT MODEL MARKET BY REGION 2017-2025 ($ THOUSAND)
TABLE 29 GLOBAL OTHER RAT MODEL MARKET BY REGION 2017-2025 ($ THOUSAND)
TABLE 30 GLOBAL RAT MODEL MARKET BY REGION 2017-2025 ($ MILLION)
TABLE 31 NORTH AMERICA RAT MODEL MARKET BY COUNTRY 2017-2025 ($ MILLION)
TABLE 32 BUDGET AUTHORITY BY ACTIVITY IN THE U.S. 2015-2017 ($ MILLION)
TABLE 33 EUROPE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 34 ASIA PACIFIC RAT MODEL MARKET BY COUNTRY 2017-2025 ($ THOUSAND)
TABLE 35 SNAPSHOT OF FEDERAL R&D INCENTIVES FOR CHINESE PHARMACEUTICAL COMPANIES & CROS
TABLE 36 SUMMARY OF FEDERAL R&D INCENTIVES FOR PHARMACEUTICAL COMPANIES & CROS IN INDIA
TABLE 37 SUMMARY OF FEDERAL R&D INCENTIVES FOR AUSTRALIAN PHARMACEUTICAL COMPANIES & CROS
TABLE 38 REST OF THE WORLD RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE LIST
FIGURE 1 GLOBAL RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 2 NUMBER OF EXPERIMENTAL PROCEDURES OF ANIMALS IN U.S. IN 2016
FIGURE 3 TOP COMPANIES BASED ON IN VITRO DIAGNOSTICS REVENUE IN 2016 ($ MILLION)
FIGURE 4 HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES AS % OF THEIR GDP 2016
FIGURE 5 GLOBAL RATS MODEL MARKET BY INBRED RATS TYPE 2017-2025 ($ THOUSAND)
FIGURE 6 GLOBAL RATS MODEL MARKET BY GENETICALLY ENGINEERED RATS 2017-2025 ($ THOUSAND)
FIGURE 7 GLOBAL RATS MODEL MARKET BY HYBRID RATS TYPE 2017-2025 ( $ THOUSAND)
FIGURE 8 GLOBAL RATS MODEL MARKET BY OUTBRED RATS 2017-2025 ($ THOUSAND)
FIGURE 9 GLOBAL RATS MODEL MARKET BY IMMUNE DEFICIENT RATS 2017-2025 ($ THOUSAND)
FIGURE 10 GLOBAL RATS MODEL MARKET BY SURGICALLY MODIFIED RATS 2017-2025 ($ THOUSAND)
FIGURE 11 GLOBAL RATS MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSANDS)
FIGURE 12 GLOBAL RATS MODEL MARKET BY NUCLEAR TRANSFER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 13 GLOBAL RATS MODEL MARKET BY MICRO INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 14 GLOBAL RATS MODEL MARKET BY EMBRYONIC STEM CELL INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 15 GLOBAL RATS MODEL MARKET BY OTHER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 16 RAT CARE PRODUCTS BY TYPE 2016 (%)
FIGURE 17 GLOBAL RAT CARE PRODUCT MARKET BY FEED 2017-2025 ($ THOUSAND)
FIGURE 18 GLOBAL RAT CARE PRODUCT MARKET BY BEDDING 2017-2025 ($ THOUSAND)
FIGURE 19 GLOBAL RAT CARE PRODUCT MARKET BY CAGES 2017-2025 ($ THOUSAND)
FIGURE 20 GLOBAL RAT MODEL MARKET BY DIABETES 2017-2025($ THOUSAND)
FIGURE 21 PERCENTAGE OF DIABETES IN WORLD ADULT POPULATION IN 1980, 2015 AND 2040
FIGURE 22 GLOBAL RAT MODEL MARKET BY TOXICOLOGY 2017-2025($ THOUSAND)
FIGURE 23 GLOBAL TOXICOLOGY RAT MODEL MARKET BY REGION 2017-2025($ THOUSAND)
FIGURE 24 GLOBAL RAT MODEL MARKET BY ONCOLOGY 2017-2025($ THOUSAND)
FIGURE 25 INCREASING COSTS OF ONCOLOGY THERAPEUTICS AND SUPPORTIVE CARE DRUGS ($ BILLION)
FIGURE 26 GLOBAL RAT MODEL MARKET BY IMMUNOLOGY & INFLAMMATION 2017-2025 ($ THOUSAND)
FIGURE 27 GLOBAL RAT MODEL MARKET BY OTHER 2017-2025 ($ THOUSAND)
FIGURE 28 PORTERS 5 FORCE MODEL OF RAT MODEL
FIGURE 29 BIOTECHNOLOGY FIRMS ACROSS COUNTRIES 2016
FIGURE 30 WORLDWIDE TOTAL PHARMACEUTICAL R&D EXPENDITURE 2014-2020 ($ BILLION)
FIGURE 31 NORTH AMERICA RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 32 NATIONAL HUMAN GENOME RESEARCH BUDGET, 2017 ($ MILLION)
FIGURE 33 U.S. PHARMACEUTICAL INDUSTRY EXPENDITURE ON R&D 2012-2015 ($ BILLION)
FIGURE 34 U.S. RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 35 FUNDS ALLOCATED FOR RESEARCH ACTIVITIES IN BUDGET 2016
FIGURE 36 CANADIAN PHARMACEUTICAL MARKET 2015 & 2020 ($ BILLION)
FIGURE 37 CANADA RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 38 EUROPE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 39 UNITED KINGDOM RAT MODELS MARKET 2017-2025 ($ THOUSAND)
FIGURE 40 FRANCE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 41 GERMANY RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 42 SPAIN RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 43 ITALY RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 44 REST OF EUROPE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 45 ASIA PACIFIC RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 46 CHINESE PHARMACEUTICAL MARKET 2015-2020 ($ BILLION)
FIGURE 47 CHINA RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 48 BUDGET ALLOCATION FOR DEPARTMENT OF SCIENCE AND TECHNOLOGY ($ MILLION)
FIGURE 49 INDIA RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 50 GROSS EXPENDITURE ON R&D IN JAPAN 2014-2016 ($ BILLION)
FIGURE 51 JAPAN RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 52 SOUTH KOREA’S PHARMACEUTICAL MARKET 2016-2020 ($ BILLION)
FIGURE 53 SOUTH KOREA RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 54 AUSTRALIA RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 55 REST OF ASIA-PACIFIC RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 56 REST OF THE WORLD RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 57 LATIN AMERICA RAT MODEL MARKET 2017-2025($ THOUSAND)
FIGURE 58 MIDDLE EAST AND NORTH AFRICA RAT MODEL MARKET 2017-2025($ THOUSAND)
FIGURE 59 AFRICA RAT MODEL MARKET 2017-2025($ THOUSAND)
FIGURE 60 MARKET SHARE ANALYSIS OF GLOBAL RAT MODEL MARKET 2015
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. IMPROVEMENT IN GENOME EDITING
4.1.2. FAST AND INCREASING AVAILABILITY IN RAT TRANSGENIC
4.1.3. INCREASING PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES R&D
4.2. MARKET RESTRAINTS
4.2.1. PRACTICE OF ANIMALS IN RESEARCH IS CONSIDERED UNETHICAL
4.2.2. FLUCTUATING RULES AND REGULATION ON ANIMAL TESTING
4.2.3. USE OF ZEBRA FISH IN RESEARCH IS THE GROWING MODEL
4.2.4. IN VITRO AND ALTERNATIVE TESTING TECHNIQUES MODELS FOR RESEARCH
4.3. MARKET OPPORTUNITIES
4.3.1. RISING DEMAND OF RAT MODEL FOR RESEARCH ACTIVITIES FROM EMERGENT ECONOMIES
4.3.2. PERSONALIZED MEDICINE ESTABLISHED TO SURGE DEMAND
4.3.3. ESCALATION IN MONOCLONAL ANTIBODY CREATION
4.4. MARKET CHALLENGES
4.4.1. RAT MODEL IS HIGHLY EXPENSIVE
5. MARKET SEGMENTATION
5.1. BY RAT MODEL TYPES
5.1.1. INBRED RATS
5.1.2. KNOCKOUT/GENETICALLY ENGINEERED RATS
5.1.3. HYBRID/CONGENIC RATS
5.1.4. OUTBRED RATS
5.1.5. IMMUNE-DEFICIENT RATS
5.1.6. CONDITIONED/SURGICALLY MODIFIED RATS
5.2. BY COMPONENTS
5.2.1. TECHNOLOGY
5.2.1.1. NUCLEAR TRANSFERASE TECHNOLOGY
5.2.1.2. MICROINJECTION
5.2.1.3. EMBRYONIC STEM CELL INJECTION
5.2.1.4. OTHER TECHNOLOGY
5.2.2. SERVICES
5.2.3. RAT CARE PRODUCTS
5.2.3.1. FEED
5.2.3.2. BEDDING
5.2.3.3. CAGES
5.2.3.4. OTHER CARE PRODUCTS
5.3. BY APPLICATION
5.3.1. DIABETES
5.3.2. TOXICOLOGY
5.3.3. ONCOLOGY
5.3.4. IMMUNOLOGY & INFLAMMATION
5.3.5. OTHER
6. KEY ANALYTICS
6.1. PORTERS 5 FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCT
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. VALUE CHAIN ANALYSIS
6.4. OPPORTUNITY MATRIX
6.5. REGULATORY FRAMEWORK
6.6. ESTIMATION ANALYSIS
6.6.1. GLOBAL BIOTECH INVESTMENT
6.6.2. BIOTECHNOLOGY FIRMS ACROSS COUNTRIES
6.6.3. GLOBAL PHARMACEUTICAL RESEARCH & DEVELOPMENT EXPENDITURE
6.6.4. GLOBAL BIOTECH R&D EXPENDITURE
6.7. KEY BUYING CRITERIA
6.7.1. HIGH ACCURACY
6.7.2. HIGH EFFICACY
6.7.3. QUALITY OF OPERATING PROCEDURE
6.7.4. PRICE
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. U.S.
7.1.2. CANADA
7.2. EUROPE
7.2.1. UNITED KINGDOM
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. SPAIN
7.2.5. ITALY
7.2.6. REST OF EUROPE (ROE)
7.3. ASIA PACIFIC
7.3.1. CHINA
7.3.2. INDIA
7.3.3. JAPAN
7.3.4. SOUTH KOREA
7.3.5. AUSTRALIA
7.3.6. REST OF ASIA-PACIFIC
7.4. REST OF THE WORLD
7.4.1. LATIN AMERICA
7.4.2. MIDDLE EAST AND NORTH AFRICA
7.4.3. AFRICA
8. COMPETITIVE ANALYSIS
8.1. KEY STRATEGIES AND ANALYSIS
8.1.1. MERGER & ACQUISITION (M&A)
8.1.2. COLLABORATION & PARTNERSHIPS
8.1.3. INVESTMENT / PRODUCT LAUNCH
8.2. MARKET SHARE
8.3. TOP COMPANY ANALYSIS
8.4. LIST OF M&A
8.5. COLLABORATION & PARTNERSHIP
8.6. LIST OF PRODUCT LAUNCHES
9. COMPANY PROFILE
9.1. BIOMEDICAL RESEARCH MODEL INC.
9.1.1. COMPANY OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.2. CHARLES RIVER LABORATORIES INC.
9.2.1. COMPANY OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. KEY INNOVATION SECTOR
9.2.4. STRATEGIC INITIATIVES
9.2.5. SCOT ANALYSIS
9.3. COVANCE INC. (LABCORP HOLDING COMPANY)
9.3.1. COMPANY OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. KEY INNOVATION SECTOR
9.3.4. STRATEGIC INITIATIVES
9.3.5. SCOT ANALYSIS
9.4. GENOWAY S. A.
9.4.1. COMPANY OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. KEY INNOVATION SECTOR
9.4.4. STRATEGIC INITIATIVES
9.4.5. SCOT ANALYSIS
9.5. HARLAN LABORATORIES, INC. (ENVIGO, INC. HOLDING COMPANY)
9.5.1. COMPANY OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC INITIATIVES
9.5.4. SCOT ANALYSIS
9.6. JANVIER LABS
9.6.1. COMPANY OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. SAGE LABS INC (HORIZON DISCOVERY GROUP PLC HOLDING COMPANY)
9.7.1. COMPANY OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVES
9.7.4. SCOT ANALYSIS
9.8. TACONIC BIOSCIENCES
9.8.1. COMPANY OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. KEY INNOVATION SECTOR
9.8.4. STRATEGIC INITIATIVES
9.8.5. SCOT ANALYSIS
9.9. TRANSPOSAGEN BIOPHARMACEUTICALS INC
9.9.1. COMPANY OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. KEY INNOVATION SECTOR
9.9.4. STRATEGIC INITIATIVES
9.9.5. SCOT ANALYSIS
9.10. TRANSVIRAGEN INC.
9.10.1. COMPANY OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. HERA BIOLABS INC.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. KEY INNOVATION SECTOR
9.11.4. STRATEGIC INITIATIVE
9.11.5. SCOT ANALYSIS
9.12. ONCODESIGN S.A.
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. KEY INNOVATION SECTOR
9.12.4. STRATEGIC INITIATIVE
9.12.5. SCOT ANALYSIS
9.13. CYAGEN BIOSCIENCES INC.
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. KEY INNOVATION SECTOR
9.13.4. STRATEGIC INITIATIVE
9.13.5. SCOT ANALYSIS
9.14. IVO BIOTECH LTD.
9.14.1. COMPANY OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC INITIATIVES
9.14.4. SCOT ANALYSIS
9.15. CLEA JAPAN
9.15.1. COMPANY OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC INITIATIVES
9.15.4. KEY INNOVATION SECTOR
9.15.5. SCOT ANALYSIS
9.16. TRANSVIRAGEN, INC.
9.16.1. COMPANY OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC INITIATIVES
9.16.4. KEY INNOVATION SECTOR
9.16.5. SCOT ANALYSIS
9.17. BIOMERE
9.17.1. COMPANY OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC INITIATIVES
9.17.4. KEY INNOVATION SECTOR
9.17.5. SCOT ANALYSIS
9.18. LABORATORY CORPORATION OF AMERICA HOLDINGS
9.18.1. COMPANY OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. STRATEGIC INITIATIVES
9.18.4. KEY INNOVATION SECTOR
9.18.5. SCOT ANALYSIS
TABLE LIST
TABLE 1 GLOBAL RAT MODEL MARKET BY GEOGRAPHIC REGION 2017-2025 ($ THOUSAND)
TABLE 2 BENEFITS OF RATS
TABLE 3 GLOBAL RATS MODEL MARKET BY RAT TYPES 2017-2025 ($ THOUSAND)
TABLE 4 EXAMPLES OF INBRED RATS AND THERE RESEARCH APPLICATIONS
TABLE 5 GLOBAL INBRED RATS TYPE BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 6 GLOBAL GENETICALLY ENGINEERED RATS MARKET BY GEOGRAPHY 2017-2025($ THOUSAND)
TABLE 7 GLOBAL HYBRID RATS MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 8 EXAMPLES OF OUTBRED RATS AND THERE RESEARCH APPLICATIONS
TABLE 9 GLOBAL OUTBRED RATS MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 10 GLOBAL IMMUNE DEFICIT RATS MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 11 GLOBAL SURGICALLY MODIFIED RATS MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 12 GLOBAL RATS MODEL MARKET BY COMPONENTS 2017-2025 ($ THOUSAND)
TABLE 13 GLOBAL RATS MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 14 GLOBAL NUCLEAR TRANSFER TECHNOLOGY BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 15 GLOBAL MICRO INJECTION TECHNOLOGY BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 16 GLOBAL EMBRYONIC STEM CELL INJECTION TECHNOLOGY BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 17 GLOBAL OTHER TECHNOLOGY RAT MODEL MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 18 GLOBAL RAT MODEL SERVICES MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 19 GLOBAL RAT MODEL MARKET BY RAT CARE PRODUCTS 2017-2025 ($ THOUSAND)
TABLE 20 GLOBAL RAT FEED MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 21 POPULAR FOOD FOR RATS
TABLE 22 GLOBAL RAT BEDDING MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 23 GLOBAL RAT CAGES MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 24 GLOBAL RAT CARE OTHERS MARKET BY GEOGRAPHY 2017-2025 ($ THOUSAND)
TABLE 25 GLOBAL RAT MODEL MARKET BY APPLICATION 2017-2025($ THOUSAND)
TABLE 26 GLOBAL DIABETES RAT MODEL MARKET BY REGION 2017-2025($ THOUSAND)
TABLE 27 GLOBAL ONCOLOGY RAT MODEL MARKET BY REGION 2017-2025($ THOUSAND)
TABLE 28 GLOBAL IMMUNOLOGY & INFLAMMATION RAT MODEL MARKET BY REGION 2017-2025 ($ THOUSAND)
TABLE 29 GLOBAL OTHER RAT MODEL MARKET BY REGION 2017-2025 ($ THOUSAND)
TABLE 30 GLOBAL RAT MODEL MARKET BY REGION 2017-2025 ($ MILLION)
TABLE 31 NORTH AMERICA RAT MODEL MARKET BY COUNTRY 2017-2025 ($ MILLION)
TABLE 32 BUDGET AUTHORITY BY ACTIVITY IN THE U.S. 2015-2017 ($ MILLION)
TABLE 33 EUROPE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 34 ASIA PACIFIC RAT MODEL MARKET BY COUNTRY 2017-2025 ($ THOUSAND)
TABLE 35 SNAPSHOT OF FEDERAL R&D INCENTIVES FOR CHINESE PHARMACEUTICAL COMPANIES & CROS
TABLE 36 SUMMARY OF FEDERAL R&D INCENTIVES FOR PHARMACEUTICAL COMPANIES & CROS IN INDIA
TABLE 37 SUMMARY OF FEDERAL R&D INCENTIVES FOR AUSTRALIAN PHARMACEUTICAL COMPANIES & CROS
TABLE 38 REST OF THE WORLD RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE LIST
FIGURE 1 GLOBAL RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 2 NUMBER OF EXPERIMENTAL PROCEDURES OF ANIMALS IN U.S. IN 2016
FIGURE 3 TOP COMPANIES BASED ON IN VITRO DIAGNOSTICS REVENUE IN 2016 ($ MILLION)
FIGURE 4 HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES AS % OF THEIR GDP 2016
FIGURE 5 GLOBAL RATS MODEL MARKET BY INBRED RATS TYPE 2017-2025 ($ THOUSAND)
FIGURE 6 GLOBAL RATS MODEL MARKET BY GENETICALLY ENGINEERED RATS 2017-2025 ($ THOUSAND)
FIGURE 7 GLOBAL RATS MODEL MARKET BY HYBRID RATS TYPE 2017-2025 ( $ THOUSAND)
FIGURE 8 GLOBAL RATS MODEL MARKET BY OUTBRED RATS 2017-2025 ($ THOUSAND)
FIGURE 9 GLOBAL RATS MODEL MARKET BY IMMUNE DEFICIENT RATS 2017-2025 ($ THOUSAND)
FIGURE 10 GLOBAL RATS MODEL MARKET BY SURGICALLY MODIFIED RATS 2017-2025 ($ THOUSAND)
FIGURE 11 GLOBAL RATS MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSANDS)
FIGURE 12 GLOBAL RATS MODEL MARKET BY NUCLEAR TRANSFER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 13 GLOBAL RATS MODEL MARKET BY MICRO INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 14 GLOBAL RATS MODEL MARKET BY EMBRYONIC STEM CELL INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 15 GLOBAL RATS MODEL MARKET BY OTHER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 16 RAT CARE PRODUCTS BY TYPE 2016 (%)
FIGURE 17 GLOBAL RAT CARE PRODUCT MARKET BY FEED 2017-2025 ($ THOUSAND)
FIGURE 18 GLOBAL RAT CARE PRODUCT MARKET BY BEDDING 2017-2025 ($ THOUSAND)
FIGURE 19 GLOBAL RAT CARE PRODUCT MARKET BY CAGES 2017-2025 ($ THOUSAND)
FIGURE 20 GLOBAL RAT MODEL MARKET BY DIABETES 2017-2025($ THOUSAND)
FIGURE 21 PERCENTAGE OF DIABETES IN WORLD ADULT POPULATION IN 1980, 2015 AND 2040
FIGURE 22 GLOBAL RAT MODEL MARKET BY TOXICOLOGY 2017-2025($ THOUSAND)
FIGURE 23 GLOBAL TOXICOLOGY RAT MODEL MARKET BY REGION 2017-2025($ THOUSAND)
FIGURE 24 GLOBAL RAT MODEL MARKET BY ONCOLOGY 2017-2025($ THOUSAND)
FIGURE 25 INCREASING COSTS OF ONCOLOGY THERAPEUTICS AND SUPPORTIVE CARE DRUGS ($ BILLION)
FIGURE 26 GLOBAL RAT MODEL MARKET BY IMMUNOLOGY & INFLAMMATION 2017-2025 ($ THOUSAND)
FIGURE 27 GLOBAL RAT MODEL MARKET BY OTHER 2017-2025 ($ THOUSAND)
FIGURE 28 PORTERS 5 FORCE MODEL OF RAT MODEL
FIGURE 29 BIOTECHNOLOGY FIRMS ACROSS COUNTRIES 2016
FIGURE 30 WORLDWIDE TOTAL PHARMACEUTICAL R&D EXPENDITURE 2014-2020 ($ BILLION)
FIGURE 31 NORTH AMERICA RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 32 NATIONAL HUMAN GENOME RESEARCH BUDGET, 2017 ($ MILLION)
FIGURE 33 U.S. PHARMACEUTICAL INDUSTRY EXPENDITURE ON R&D 2012-2015 ($ BILLION)
FIGURE 34 U.S. RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 35 FUNDS ALLOCATED FOR RESEARCH ACTIVITIES IN BUDGET 2016
FIGURE 36 CANADIAN PHARMACEUTICAL MARKET 2015 & 2020 ($ BILLION)
FIGURE 37 CANADA RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 38 EUROPE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 39 UNITED KINGDOM RAT MODELS MARKET 2017-2025 ($ THOUSAND)
FIGURE 40 FRANCE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 41 GERMANY RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 42 SPAIN RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 43 ITALY RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 44 REST OF EUROPE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 45 ASIA PACIFIC RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 46 CHINESE PHARMACEUTICAL MARKET 2015-2020 ($ BILLION)
FIGURE 47 CHINA RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 48 BUDGET ALLOCATION FOR DEPARTMENT OF SCIENCE AND TECHNOLOGY ($ MILLION)
FIGURE 49 INDIA RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 50 GROSS EXPENDITURE ON R&D IN JAPAN 2014-2016 ($ BILLION)
FIGURE 51 JAPAN RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 52 SOUTH KOREA’S PHARMACEUTICAL MARKET 2016-2020 ($ BILLION)
FIGURE 53 SOUTH KOREA RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 54 AUSTRALIA RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 55 REST OF ASIA-PACIFIC RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 56 REST OF THE WORLD RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 57 LATIN AMERICA RAT MODEL MARKET 2017-2025($ THOUSAND)
FIGURE 58 MIDDLE EAST AND NORTH AFRICA RAT MODEL MARKET 2017-2025($ THOUSAND)
FIGURE 59 AFRICA RAT MODEL MARKET 2017-2025($ THOUSAND)
FIGURE 60 MARKET SHARE ANALYSIS OF GLOBAL RAT MODEL MARKET 2015
